Eight Cycles May Be the Sweet Spot for Fertility Drugs in PCOS, Study Finds

For millions of women with polycystic ovary syndrome, one of the most agonizing questions in fertility treatment is deceptively simple: how many rounds of ovulation-inducing medication should you try before moving on to something more invasive? A new prospective study from researchers at Sun Yat-sen University’s First Affiliated Hospital in Guangzhou, China, offers one of the most direct answers yet. Following 655 women through 2,633 treatment cycles, the team found that the cumulative chance of delivering a baby plateaus after eight cycles of ovulation induction with timed intercourse in patients who respond well to letrozole or clomiphene citrate. Beyond that point, the data suggest, additional cycles of the same therapy add little benefit, and couples and clinicians may reasonably consider stepping up to more advanced reproductive technologies.

Polycystic ovary syndrome, or PCOS, is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular or absent ovulation, elevated androgen levels, and polycystic ovarian morphology on ultrasound. Because anovulation is the primary barrier to conception for many of these patients, the first-line treatment is typically oral medication that nudges the ovary to release an egg. Letrozole, an aromatase inhibitor originally developed for breast cancer, and clomiphene citrate, a selective estrogen receptor modulator used for decades, are the two workhorses of this approach. When ovulation is successfully induced, couples are advised to time intercourse to the fertile window, avoiding the cost and complexity of intrauterine insemination or in vitro fertilization, at least initially.

What has been missing from clinical guidance is a well-defined stopping point. International guidelines recommend ovulation induction as first-line therapy for anovulatory PCOS, but they offer limited evidence on how many cycles a patient should complete before the therapy is deemed exhausted. Continuing too long exposes women to repeated monitoring, medication, and emotional strain with diminishing returns; stopping too early may abandon a therapy that would eventually have worked. The Chinese team, led by Yuanlin Ma and corresponding author Qingyun Mai, set out to quantify that inflection point using cumulative live birth rate, the metric that fertility specialists regard as the most meaningful measure of treatment success because it counts the outcome patients actually care about: taking home a baby.

The study was designed as a prospective cohort investigation conducted between August 1, 2020, and June 30, 2023. Crucially, the researchers restricted enrollment to women whose ovaries had already demonstrated sensitivity to letrozole or clomiphene citrate, confirmed through hospital-based monitoring during the first treatment cycle. This design choice matters scientifically: rather than asking whether the drugs work in general, the investigators isolated the question of how many cycles a confirmed responder should continue. After that first monitored cycle, subsequent cycles were managed with home ovulation monitoring, a pragmatic real-world approach that reflects how most patients actually experience treatment outside of specialized research protocols.

The headline numbers tell a story of steady but finite returns. Of the 655 women enrolled, 306 achieved 372 pregnancies, of which 257 progressed to clinical pregnancy and 206 ended in live birth. Expressed as cumulative rates over the whole cohort, 46.72 percent of women achieved pregnancy, 39.24 percent achieved a clinical pregnancy, and 31.45 percent delivered at least one live baby. When the researchers plotted cumulative live birth rate against cycle number, the curve climbed briskly through the early cycles and then flattened decisively after the eighth cycle. In other words, the vast majority of the eventual success was captured within roughly a year and a half of attempted cycles, and cycles nine and beyond contributed almost nothing to the total.

The technical logic behind a cumulative live birth curve is worth unpacking, because it explains why this kind of analysis is so useful. Each cycle carries a per-cycle probability of success, and the cumulative rate aggregates those probabilities across successive attempts, accounting for the fact that women who conceive early drop out of the denominator of those still trying. A plateau in the cumulative curve signals that the residual per-cycle success rate among women still attempting has fallen so low that further cycles barely move the total. This is the same statistical framework used to counsel patients about in vitro fertilization, where cumulative live birth curves typically plateau after a certain number of egg retrieval attempts. Applying it to oral ovulation induction gives clinicians an evidence-based benchmark for a therapy that has long been guided by convention rather than data.

Two secondary findings from the study may prove just as consequential as the headline plateau. First, the researchers found that weight reduction was associated with a substantial boost in the maximal cumulative live birth rate, lifting it from 28.00 percent in the cohort overall to 39.02 percent among patients who lost weight. This aligns with a deep body of evidence that even modest weight loss in overweight women with PCOS can restore ovulatory function, improve insulin sensitivity, and enhance endometrial receptivity. The finding underscores that lifestyle intervention is not merely an adjunct to pharmaceutical treatment but can meaningfully amplify its yield, potentially changing the calculus of how many cycles are worth pursuing.

Second, metformin use was associated with reaching the cumulative live birth plateau earlier. Metformin, an insulin-sensitizing agent widely prescribed in PCOS, is thought to improve ovulatory function by addressing the hyperinsulinemia that drives many of the syndrome’s reproductive disturbances. If patients on metformin achieve their maximal cumulative benefit in fewer cycles, that has practical implications for treatment planning: it suggests the drug may accelerate the path to success among responders, allowing couples to reach either a live birth or a decision to escalate to assisted reproduction sooner. The researchers also stratified their analyses by PCOS phenotype, comparing patients with the classic hyperandrogenic presentation against those with ovulatory dysfunction and polycystic morphology without elevated androgens, acknowledging that PCOS is not a single entity but a spectrum.

The study’s strengths lie in its size, its prospective design, and its focus on a well-defined, clinically relevant population of drug-sensitive patients, all tracked through more than two and a half thousand monitored cycles. Its limitations are those inherent to a single-center observational cohort: the findings may not generalize to women who do not respond to first-line oral agents, to centers with different monitoring practices, or to populations with different baseline characteristics. The authors also note that the analysis was conducted on an intention-to-treat basis, which preserves real-world validity but cannot fully disentangle why some women discontinued treatment early. As with any cohort study, the associations with weight loss and metformin reflect patterns in the data rather than the results of randomized manipulation.

Even with those caveats, the practical message is strikingly clear for patients and clinicians navigating the early stages of fertility care. For women with PCOS who ovulate on letrozole or clomiphene citrate, eight cycles of ovulation induction with timed intercourse appear sufficient to capture the maximal cumulative live birth rate that this therapy can deliver, with weight loss and metformin offering avenues to improve the odds within that window. Couples who have not achieved a live birth by that point now have data-driven grounds to discuss escalation to intrauterine insemination or in vitro fertilization rather than continuing indefinitely down the same path. In a field where treatment decisions have often rested on tradition and intuition, a concrete, quantified stopping rule is a rare and welcome piece of clarity, and one that could spare countless patients months of futile cycles and the emotional toll that accompanies them.

Subject of Research: Optimal number of ovulation induction cycles with timed intercourse in letrozole- or clomiphene citrate-sensitive polycystic ovary syndrome

Article Title: When to stop? assessing the appropriate cycle of ovulation induction with timed intercourse in letrozole- or clomiphene citrate-sensitive polycystic ovary syndrome

Article References: Ma, Y., Liang, Q., Wen, T., Wang, C., Hu, R., Jie, H., Xu, Y., & Mai, Q. (2026). When to stop? assessing the appropriate cycle of ovulation induction with timed intercourse in letrozole- or clomiphene citrate-sensitive polycystic ovary syndrome. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02283-8

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02283-8

Keywords: polycystic ovary syndrome, ovulation induction, letrozole, clomiphene citrate, cumulative live birth rate, timed intercourse, fertility treatment, metformin, weight loss, infertility, reproductive medicine, anovulation